Core Insights - Recently, Ruizhi Pharmaceutical and Megia Technology officially signed a strategic cooperation agreement aimed at "building an intelligent biomanufacturing ecosystem to lead industry transformation" [1] - The collaboration will leverage Megia's AI-Agent technology and Ruizhi's advanced preclinical research capabilities along with high-quality data assets to create an "AI-driven automated laboratory for biomedicine" that is both evolvable and deployable [1] - This partnership marks a new phase in the evolution of AI from being an auxiliary tool to becoming a core infrastructure, systematically enhancing the quality and efficiency of drug development and establishing a benchmark project for AI automation in innovative drug research [1]